Prostate Cancer Precision Prevention Program

Interested in learning more about our screening programs or partnerships?

Please contact us at

Prostate cancer is the most common cancer affecting men. Even though it often has a good prognosis, it is still a significant cause of morbidity.

Screening for prostate cancer is one of the most controversial topics in the urological literature. The European Association of Urology supports measures to encourage appropriate prostate cancer detection through PSA testing whilst considering age, family history, and ethnicity.

However, recent data suggest that this standard of care by itself is insufficient as prostate cancer risk has significant heritability, estimated at 57%. More than 160 prostate cancer risk-associated SNPs have been identified through genetic studies. Risk-associated SNPs can be combined into a polygenic risk score (PRS) estimate that is a better predictor of prostate cancer than family history. Recent studies have suggested that a PRS based screening program might reduce over-diagnostics whilst maintain the age benefits of age-based screening (Callender, Emberton et al. 2019).

AntePC is a polygenic risk score genetic test developed by Antegenes that measures men’s risk of developing prostate cancer and aims to reduce the risk of premature prostate cancer mortality by recommending individualized screening designs.

To support this, we have developed a prostate cancer precision prevention program. The precision prevention program uses individual polygenic risks identified by AntePC to give individualized recommendations for performing prostate cancer PSA-based screening. Clinical recommendations of AntePC are based on evidence-based data on prostate cancer risk factors, screening and preventive measures, and the corresponding recommendations of international medical organizations.

AntePC is included in the prostate cancer precision prevention program and is suitable for men aged 40-75.


  1. Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. Jama. 2016;315(1):68-76.
  2. Callender T, Emberton M, Morris S, Eeles R, Kote-Jarai Z, Pharoah PDP, et al. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. PLoS Med. 2019;16(12):e1002998.
  3. Na R, Labbate C, Yu H, Shi Z, Fantus RJ, Wang CH, et al. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis. JAMA Netw Open. 2019;2(12):e1918145.
  4. Xu J, Labbate CV, Isaacs WB, Helfand BT. Inherited risk assessment of prostate cancer: it takes three to do it right. Prostate Cancer Prostatic Dis. 2019.